contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inhalation-sciences-secures-188900-euro-order-from-top-five-global-generics-manufacturer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB's in ...

<div class="abstract">Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project. The client has once again chosen DissolvIt, ISAB's in vitro dissolution testing module, known for its precise prediction and comparison of how test generic formulations and originator products perform in the lung. DissolvIt provides a unique advantage for developers of complex generic inhaled therapies. DissolvIt testing is being adopted by a growing number of generic and novel biopharma companies.</div>The returning client is amongst the world's top five generic pharma' manufacturers and has commissioned the project as a follow-up to a previous study, this time comparing a range of inhaled formulations. &nbsp;DissolvIt a critical enabler of inhaled pharmaceuticalsThe scale and value of the project underscores DissolvIt's growing reputation and leading capabilities in preclinical in vitro dissolution testing. For developers of inhaled pharmaceuticals, DissolvIt's ability to generate reliable comparative data on substances in the preclinical phase and how they will behave in the clinical phase delivers valuable benefits, reducing risk, costs and, potentially, regulatory hurdles.Particularly in the US, DissolvIt could prove to be an enabler for increasing the number of inhaled generic pharmaceutical treatments available on the market, a sought-after goal for both the industry and healthcare sector. The cost of clinical tests required in the US has contributed to few commercially available inhaled generics. Only 15% of the 62 inhalers for asthma and COPD approved by the FDA between 1986 and 2020 were generics (1).DissolvIt's capabilities are currently being evaluated in an FDA BAA (Broad Agency Announcement) contract research project at Inhalation Sciences' facilities in Huddinge, Sweden.CEO Manoush Masarrat: "We're seeing preclinical&nbsp;in vitro&nbsp;testing gaining traction industry-wide, in particular amongst innovative and generic drug developers. DissolvIt stands at the forefront of this exciting field. We're pleased to welcome this esteemed client back to Inhalation Sciences and our services".Discover DissolvIt[® ]Read ISAB's publications on&nbsp;DissolvIt[®]here.&nbsp;(<a href="https://www.inhalation.se/publications/">https://www.inhalation.se/publications/</a>)Discover DissolvIt's in vitro&nbsp;capabilities&nbsp;here.&nbsp;(<a href="https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/">https://www.inhalation.se/inhalation-research-services/dissolvit-in-vitro-dissolution/</a>)Explore Inhalation Research Services here&nbsp;(<a href="https://www.inhalation.se/inhalation-research-services/">https://www.inhalation.se/inhalation-research-services/</a>).1. Patents and regulatory exclusivities on inhalers for asthma and COPD, 1986-2020 William B. Feldman, Doni Bloomfield, Reed Beall, Aaron S. Kesselheim

Inhalation Sciences secures 188,900 Euro order from top-five global generics manufacturer